Inflammatory bowel disease in pregnancy and breastfeeding

The treatment landscape of inflammatory bowel disease (IBD) is constantly evolving, including among pregnant women and those who wish to become pregnant. This Review provides a detailed update on the management of patients with IBD during pregnancy and breastfeeding. Inflammatory bowel disease (IBD) has a peak age of diagnosis before the age of 35 years. Concerns about infertility, adverse pregnancy outcomes, and heritability of IBD have influenced decision-making for patients of childbearing age and their care providers. The interplay between the complex physiology in pregnancy and IBD can affect placental development, microbiome composition and responses to therapy. Current evidence has shown that effective disease management, including pre-conception counselling, multidisciplinary care and therapeutic agents to minimize disease activity, can improve pregnancy outcomes. This Review outlines the management of IBD in pregnancy and the safety of IBD therapies, including novel agents, with regard to both maternal and fetal health. The vast majority of IBD therapies can be used with low risk during pregnancy and lactation without substantial effects on neonatal outcomes.

Automated summary

This review provides an update on the management of inflammatory bowel disease (IBD) during pregnancy and breastfeeding. Effective disease management, including pre-conception counseling and therapeutic agents, can improve pregnancy outcomes for women with IBD.